PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 27131780-4 2016 To further investigate this latter effect, we tested whether CBD (15-60mg/kg) would attenuate the catalepsy and c-Fos protein expression in the dorsal striatum induced by haloperidol (0.6mg/kg). Haloperidol 171-182 FBJ osteosarcoma oncogene Mus musculus 112-117 30296459-7 2019 Furthermore, ouabain-injected mice exhibited the increase in the number of c-fos-positive cells in the nucleus accumbens and the prefrontal cortex but not in the ventral tegmental area, which was reduced by haloperidol. Haloperidol 207-218 FBJ osteosarcoma oncogene Mus musculus 75-80 30713996-5 2018 In case of typical antipsychotics such as Haloperidol, the c-fos active cells were predominantly found in the striatum, whereas in case of the atypical antipsychotics (Clozapine and Olanzapine), c-fos-induced cells were more numerous in the cortical regions, e.g., orbital cortex, piriform cortex. Haloperidol 42-53 FBJ osteosarcoma oncogene Mus musculus 59-64 30713996-5 2018 In case of typical antipsychotics such as Haloperidol, the c-fos active cells were predominantly found in the striatum, whereas in case of the atypical antipsychotics (Clozapine and Olanzapine), c-fos-induced cells were more numerous in the cortical regions, e.g., orbital cortex, piriform cortex. Haloperidol 42-53 FBJ osteosarcoma oncogene Mus musculus 195-200 28671605-7 2017 In addition, DCS significantly reduced HAL-induced Fos expression in the dorsolateral striatum without affecting that in the nucleus accumbens. Haloperidol 39-42 FBJ osteosarcoma oncogene Mus musculus 51-54 27658674-11 2016 Striatal D2 MSN activation in haloperidol-treated Adora2a-Cre mice increased c-Fos+ D2 MSNs and decreased c-Fos+ non-D2 MSNs, suggesting a role for c-Fos. Haloperidol 30-41 FBJ osteosarcoma oncogene Mus musculus 77-82 27658674-11 2016 Striatal D2 MSN activation in haloperidol-treated Adora2a-Cre mice increased c-Fos+ D2 MSNs and decreased c-Fos+ non-D2 MSNs, suggesting a role for c-Fos. Haloperidol 30-41 FBJ osteosarcoma oncogene Mus musculus 106-111 27658674-11 2016 Striatal D2 MSN activation in haloperidol-treated Adora2a-Cre mice increased c-Fos+ D2 MSNs and decreased c-Fos+ non-D2 MSNs, suggesting a role for c-Fos. Haloperidol 30-41 FBJ osteosarcoma oncogene Mus musculus 106-111 27131780-10 2016 Haloperidol also increased c-Fos protein expression in the dorsolateral striatum, an effect attenuated by previous CBD administration. Haloperidol 0-11 FBJ osteosarcoma oncogene Mus musculus 27-32 27131780-11 2016 CBD effects on catalepsy and c-Fos protein expression induced by haloperidol were blocked by the 5-HT1A receptor antagonist. Haloperidol 65-76 FBJ osteosarcoma oncogene Mus musculus 29-34 26256420-7 2015 The C57Bl/6 mouse also showed regionally preferential c-Fos activation by haloperidol (2 mg/kg, IP) and SKF82858 (3 mg/kg, IP). Haloperidol 74-85 FBJ osteosarcoma oncogene Mus musculus 54-59 26554387-9 2016 Haloperidol increased c-Fos immunoreactivity in anterior cingulate cortex (ACg) and nucleus accumbens (Acb) core of WT but not KO mice. Haloperidol 0-11 FBJ osteosarcoma oncogene Mus musculus 22-27 22261384-9 2012 This effect seems to be mediated by the A(2A) receptor but not the A(1) receptor, since the A(2A) antagonist MSX-3, but not the A(1) antagonist CPT, dose dependently reversed the effects of haloperidol on effort-related choice and on c-Fos expression in the dorsal striatum and nucleus accumbens. Haloperidol 190-201 FBJ osteosarcoma oncogene Mus musculus 234-239 24366052-10 2014 Lastly, but most importantly, increases in c-Fos expression and HAL efficacy in the CAR test of the HAL+VPA and HAL+MS-275 groups were correlated with elevated histone acetylation at the c-fos promoter region in aged mice. Haloperidol 100-103 FBJ osteosarcoma oncogene Mus musculus 43-48 24366052-10 2014 Lastly, but most importantly, increases in c-Fos expression and HAL efficacy in the CAR test of the HAL+VPA and HAL+MS-275 groups were correlated with elevated histone acetylation at the c-fos promoter region in aged mice. Haloperidol 100-103 FBJ osteosarcoma oncogene Mus musculus 187-192 24366052-10 2014 Lastly, but most importantly, increases in c-Fos expression and HAL efficacy in the CAR test of the HAL+VPA and HAL+MS-275 groups were correlated with elevated histone acetylation at the c-fos promoter region in aged mice. Haloperidol 100-103 FBJ osteosarcoma oncogene Mus musculus 43-48 24366052-10 2014 Lastly, but most importantly, increases in c-Fos expression and HAL efficacy in the CAR test of the HAL+VPA and HAL+MS-275 groups were correlated with elevated histone acetylation at the c-fos promoter region in aged mice. Haloperidol 100-103 FBJ osteosarcoma oncogene Mus musculus 187-192 23557694-11 2013 Although adenosine antagonists did not affect c-Fos expression on their own, theophylline and MSX-3, but not CPT, attenuated haloperidol induction of c-Fos expression. Haloperidol 125-136 FBJ osteosarcoma oncogene Mus musculus 150-155 24366052-7 2014 In addition, HAL-induced c-Fos expression in the nucleus accumbens shell and prefrontal cortex was significantly lower in aged mice as compared with young mice. Haloperidol 13-16 FBJ osteosarcoma oncogene Mus musculus 25-30 24366052-9 2014 Also, VPA and MS-275 pretreatment restored HAL-induced increases in c-Fos expression in the nucleus accumbens shell and prefrontal cortex of aged mice to levels comparable with those observed in young mice. Haloperidol 43-46 FBJ osteosarcoma oncogene Mus musculus 68-73 23142770-5 2013 This study investigated if modulation of the ErbB1-ERK1/2 pathway by clozapine, olanzapine and haloperidol affected expression of the ERK substrates p90RSK and c-Fos, factors that regulate transcription of proteins associated with neuroplasticity and synapse formation in C57Bl/6 mice. Haloperidol 95-106 FBJ osteosarcoma oncogene Mus musculus 160-165 23142770-9 2013 Alternatively, haloperidol stimulation of c-Fos levels limited to the striatum was in accord with direct transcriptional regulation through ERK. Haloperidol 15-26 FBJ osteosarcoma oncogene Mus musculus 42-47 19352073-5 2009 The anticataleptic dose of tandospirone (1 mg/kg, s.c.) significantly reduced haloperidol-induced Fos expression in the dlST. Haloperidol 78-89 FBJ osteosarcoma oncogene Mus musculus 98-101 21670104-7 2011 In addition, in mice lacking TAAR1, haloperidol-induced striatal c-Fos expression and catalepsy were significantly reduced. Haloperidol 36-47 FBJ osteosarcoma oncogene Mus musculus 65-70 20460137-7 2010 Blonanserin and haloperidol at the above doses significantly enhanced Fos expression in the shell (AcS) region of the nucleus accumbens and dorsolateral striatum (dlST). Haloperidol 16-27 FBJ osteosarcoma oncogene Mus musculus 70-73 19352073-7 2009 In addition, the reversal of haloperidol-induced striatal Fos expression by tandospirone was antagonized by WAY-100135. Haloperidol 29-40 FBJ osteosarcoma oncogene Mus musculus 58-61 18509028-11 2008 In contrast, acute haloperidol injection activated phosphorylation of ERK, MSK1, and H3 only in D2R neurons and induced c-fos and zif268 predominantly in these neurons. Haloperidol 19-30 FBJ osteosarcoma oncogene Mus musculus 120-125 18585397-0 2008 Anticataleptic 8-OH-DPAT preferentially counteracts with haloperidol-induced Fos expression in the dorsolateral striatum and the core region of the nucleus accumbens. Haloperidol 57-68 FBJ osteosarcoma oncogene Mus musculus 77-80 18585397-7 2008 Furthermore, the anticataleptic dose of 8-OH-DPAT showed a regionally specific reduction of haloperidol-induced Fos expression in the dorsolateral striatum (dlST) and the core region of the nucleus accumbens (AcC), without affecting that in the medial prefrontal cortex, the shell region of the nucleus accumbens or the lateral septal nucleus. Haloperidol 92-103 FBJ osteosarcoma oncogene Mus musculus 112-115 17318306-8 2007 Haloperidol at a dose of 1.0 mg/kg did attenuate the induction of Fos by TZG in the hippocampus but not in other brain regions. Haloperidol 0-11 FBJ osteosarcoma oncogene Mus musculus 66-69 15140647-0 2004 Role of NMDA receptor subtypes in the induction of catalepsy and increase in Fos protein expression after administration of haloperidol. Haloperidol 124-135 FBJ osteosarcoma oncogene Mus musculus 77-80 15140647-1 2004 The increase of Fos expression in the striatum induced by haloperidol, an antagonist of the dopamine D2 receptor, might be related to the activation of glutamatergic neurotransmission, especially that of N-methyl-D-aspartate (NMDA) receptors. Haloperidol 58-69 FBJ osteosarcoma oncogene Mus musculus 16-19 15140647-8 2004 These results suggest that the NMDA receptor antagonists attenuated the induction of catalepsy and Fos-IR cells in forebrain after the administration of haloperidol. Haloperidol 153-164 FBJ osteosarcoma oncogene Mus musculus 99-102 15140647-9 2004 It was also suggested that haloperidol-induced expression of Fos-IR cells in the shell region of the nucleus accumbens might be differentially regulated by NMDA receptor subunits. Haloperidol 27-38 FBJ osteosarcoma oncogene Mus musculus 61-64 11427716-3 2001 Here, we demonstrate that the ability of the typical APD haloperidol to induce Fos expression in the dorsolateral striatum is markedly attenuated in NT-null mutant mice. Haloperidol 57-68 FBJ osteosarcoma oncogene Mus musculus 79-82 14603264-7 2004 Accordingly, the effects of haloperidol on striatal c-fos, Nor-1, and dynorphin mRNA expression are also preserved in NGFI-B-deficient mice. Haloperidol 28-39 FBJ osteosarcoma oncogene Mus musculus 52-57 12048106-5 2002 Our results show that haloperidol, a DA D2-class receptor antagonist, activates c-Fos predominantly in enkephalin-positive striatal neurons, which project to the globus pallidus and are thought to mediate motor inhibition. Haloperidol 22-33 FBJ osteosarcoma oncogene Mus musculus 80-85 12048106-6 2002 Deletion of the DA D1 receptor increased the responsiveness of enkephalin neurons to haloperidol, in that haloperidol-induced increases in c-Fos and catalepsy were enhanced in D1 receptor knockout mice. Haloperidol 85-96 FBJ osteosarcoma oncogene Mus musculus 139-144 12048106-6 2002 Deletion of the DA D1 receptor increased the responsiveness of enkephalin neurons to haloperidol, in that haloperidol-induced increases in c-Fos and catalepsy were enhanced in D1 receptor knockout mice. Haloperidol 106-117 FBJ osteosarcoma oncogene Mus musculus 139-144 10940355-1 2000 We previously reported that following acute administration of haloperidol or (-)-sulpiride, both dopamine D(2)-receptor antagonists, to mice induced nerve growth factor (NGF) gene expression, mediated by the interaction of c-fos with the AP-1 binding site present in the first intron on the NGF gene. Haloperidol 62-73 FBJ osteosarcoma oncogene Mus musculus 223-228 9864262-10 1998 Haloperidol and clozapine appear to be more effective, however, in attenuating the expression of c-fos and hsp-70 in the posterior cingulate gyrus than 5-HT2 antagonists ritanserin, ketanserin or amesergide. Haloperidol 0-11 FBJ osteosarcoma oncogene Mus musculus 97-102 9221926-0 1997 Haloperidol regulates neurotensin gene expression in striatum of c-fos-deficient mice. Haloperidol 0-11 FBJ osteosarcoma oncogene Mus musculus 65-70 9578405-3 1998 The densities of Fos-, FosB-, Fra-1-, Jun- and JunD-immunoreactive nuclei induced by haloperidol and sulpiride in the hippocampus, piriform cortex and accumbens nucleus were higher than those in the control groups. Haloperidol 85-96 FBJ osteosarcoma oncogene Mus musculus 17-20 9578405-6 1998 These results suggested that induced Fos, FosB, Fra-1, Jun and JunD proteins constitute the activator protein-1 complex after the administration of haloperidol and sulpiride. Haloperidol 148-159 FBJ osteosarcoma oncogene Mus musculus 37-40 9221926-6 1997 HAL-induced NT/N mRNA levels were significantly lower in c-fos knockout mice than in WT mice on PD 10 and 15. Haloperidol 0-3 FBJ osteosarcoma oncogene Mus musculus 57-62 9571656-1 1998 The haloperidol-induced increase of Fos-like immunoreactive (Fos-li) neurons in the basal ganglia was compared in the C57BL/6J (B6) and DBA/2J (D2) inbred mouse strains. Haloperidol 4-15 FBJ osteosarcoma oncogene Mus musculus 36-39 9571656-1 1998 The haloperidol-induced increase of Fos-like immunoreactive (Fos-li) neurons in the basal ganglia was compared in the C57BL/6J (B6) and DBA/2J (D2) inbred mouse strains. Haloperidol 4-15 FBJ osteosarcoma oncogene Mus musculus 61-64 9571656-4 1998 The haloperidol effects on Fos-li neurons were examined over the range of 0.1 to 6.0 mg/kg; the ED50s for haloperidol-induced catalepsy are 0.4 and 3.8 mg/kg in the D2 and B6 strains, respectively. Haloperidol 4-15 FBJ osteosarcoma oncogene Mus musculus 27-30 9571656-4 1998 The haloperidol effects on Fos-li neurons were examined over the range of 0.1 to 6.0 mg/kg; the ED50s for haloperidol-induced catalepsy are 0.4 and 3.8 mg/kg in the D2 and B6 strains, respectively. Haloperidol 106-117 FBJ osteosarcoma oncogene Mus musculus 27-30 9221926-1 1997 The immediate-early gene c-fos has been proposed to play a role in induction of neurotensin/neuromedin N (NT/N) gene expression in the striatum following acute haloperidol (HAL) treatment. Haloperidol 160-171 FBJ osteosarcoma oncogene Mus musculus 25-30 9221926-1 1997 The immediate-early gene c-fos has been proposed to play a role in induction of neurotensin/neuromedin N (NT/N) gene expression in the striatum following acute haloperidol (HAL) treatment. Haloperidol 173-176 FBJ osteosarcoma oncogene Mus musculus 25-30 9221926-3 1997 A robust increase in NT/N gene expression was observed in the dorsolateral striatum (DLSt) in both wild-type (WT) and c-fos-deficient mice 4-6 h after a single injection of HAL (1 or 4 mg/kg) indicating that products of the c-fos gene are not absolutely required for induction of NT/N mRNA. Haloperidol 173-176 FBJ osteosarcoma oncogene Mus musculus 118-123 9221926-3 1997 A robust increase in NT/N gene expression was observed in the dorsolateral striatum (DLSt) in both wild-type (WT) and c-fos-deficient mice 4-6 h after a single injection of HAL (1 or 4 mg/kg) indicating that products of the c-fos gene are not absolutely required for induction of NT/N mRNA. Haloperidol 173-176 FBJ osteosarcoma oncogene Mus musculus 224-229 8962158-4 1996 By contrast, haloperidol, a typical neuroleptic that acts preferentially at D2-class receptors, remains effective in inducing catalepsy and striatal Fos/Jun expression in the D1 mutants, and these behavioral and neural effects can be blocked by D2 dopamine receptor agonists. Haloperidol 13-24 FBJ osteosarcoma oncogene Mus musculus 149-152 8527000-4 1995 The induction of the immediate early gene c-fos by the dopamine D2 receptor antagonist haloperidol was not altered, while the selective D1 receptor agonist SKF 38393 failed to induce c-fos in the striatum of MPTP-treated mice. Haloperidol 87-98 FBJ osteosarcoma oncogene Mus musculus 42-47 8750842-1 1995 The aim of the study was to determine whether the haloperidol-produced induction of the c-fos gene in the mouse striatum is the cause of the increased expression of the striatal proenkephalin (PENK) gene after repeated haloperidol administration. Haloperidol 50-61 FBJ osteosarcoma oncogene Mus musculus 88-93 8750842-1 1995 The aim of the study was to determine whether the haloperidol-produced induction of the c-fos gene in the mouse striatum is the cause of the increased expression of the striatal proenkephalin (PENK) gene after repeated haloperidol administration. Haloperidol 219-230 FBJ osteosarcoma oncogene Mus musculus 88-93 8750842-3 1995 Pretreatment with MK-801 prevented the haloperidol-produced induction of the striatal c-fos mRNA. Haloperidol 39-50 FBJ osteosarcoma oncogene Mus musculus 86-91 8414186-0 1993 The NMDA receptor antagonist MK-801 markedly reduces the induction of c-fos gene by haloperidol in the mouse striatum. Haloperidol 84-95 FBJ osteosarcoma oncogene Mus musculus 70-75 8414186-1 1993 The influence of the N-methyl-D-aspartate (NMDA) receptor antagonist, MK-801 (dizocilpine), on the haloperidol-induced increase of c-fos mRNA levels in the striata of mice was examined using the quantitative Northern blot analysis method. Haloperidol 99-110 FBJ osteosarcoma oncogene Mus musculus 131-136 8414186-7 1993 Higher doses of MK-801 (1.5-4.5 mg/kg) diminished c-fos mRNA increase produced by haloperidol by 80%. Haloperidol 82-93 FBJ osteosarcoma oncogene Mus musculus 50-55 33857021-5 2021 Acetaminophen prevented the haloperidol-induced decrease in the number of c-Fos+/preproenkephalin+ striatal neurons in wild-type mice but not in TRPV1-deficient mice. Haloperidol 28-39 FBJ osteosarcoma oncogene Mus musculus 74-79